Matches in SemOpenAlex for { <https://semopenalex.org/work/W1964173823> ?p ?o ?g. }
- W1964173823 endingPage "769" @default.
- W1964173823 startingPage "757" @default.
- W1964173823 abstract "The metabotropic glutamate Group II receptors (mGlu2 and mGlu3 receptors) regulate the synaptic availability of glutamate and thus control the broad-ranging neural transmission of glutamate as well as glutamate-modulated transmission. The present review focuses on the potential role of Group II mGlu receptor antagonism in neurological and neuropsychiatric disorders. Recent findings have determined that agonists of metabotropic glutamate type 2/3 receptors (mGlu2/3) have antianxiety efficacy. Although it could be assumed that blockade of these receptors might engender anxiogenic responses, new data have indicted that these compounds produce antidepressant-like, wake-promoting, and pro-cognitive effects in rodents. However, there are almost no data available to define the relative importance of mGlu2 versus mGlu3 receptors in these activities. Although there are some hints that antagonism of mGlu2/3 receptors could have additional therapeutic impact, the preponderance of data suggests that agonists of the mGlu2/3 receptors would be more likely to have efficacy in anxiety disorders, positive symptoms of schizophrenia, neurodegenerative disorders, and stroke, pain, and epilepsy. The pharmacology of antagonists of mGlu2/3 receptors suggests that such compounds could have a unique place in the medicinal arsenal for mood disorders as well as disorders of cognition and arousal. Given the activity surrounding the discovery of orally available antagonists for these receptors, there may be an opportunity for clinical investigation of these possibilities in the future. Drug Dev. Res. 67:757–769, 2006. © 2006 Wiley-Liss, Inc." @default.
- W1964173823 created "2016-06-24" @default.
- W1964173823 creator A5007514031 @default.
- W1964173823 creator A5090899159 @default.
- W1964173823 date "2006-01-01" @default.
- W1964173823 modified "2023-09-27" @default.
- W1964173823 title "Antagonism of metabotropic glutamate group II receptors in the potential treatment of neurological and neuropsychiatric disorders" @default.
- W1964173823 cites W1525839404 @default.
- W1964173823 cites W1532134440 @default.
- W1964173823 cites W1824670339 @default.
- W1964173823 cites W1913060052 @default.
- W1964173823 cites W1965246238 @default.
- W1964173823 cites W1966258577 @default.
- W1964173823 cites W1970078705 @default.
- W1964173823 cites W1976597312 @default.
- W1964173823 cites W1976996342 @default.
- W1964173823 cites W1979149627 @default.
- W1964173823 cites W1980654104 @default.
- W1964173823 cites W1983998585 @default.
- W1964173823 cites W1990246915 @default.
- W1964173823 cites W1990901763 @default.
- W1964173823 cites W1997113206 @default.
- W1964173823 cites W1999259477 @default.
- W1964173823 cites W2001564540 @default.
- W1964173823 cites W2007334584 @default.
- W1964173823 cites W2010269783 @default.
- W1964173823 cites W2010549626 @default.
- W1964173823 cites W2011373325 @default.
- W1964173823 cites W2011472568 @default.
- W1964173823 cites W2011611736 @default.
- W1964173823 cites W2011629581 @default.
- W1964173823 cites W2013588838 @default.
- W1964173823 cites W2018436424 @default.
- W1964173823 cites W2021069714 @default.
- W1964173823 cites W2022279290 @default.
- W1964173823 cites W2024787731 @default.
- W1964173823 cites W2025284542 @default.
- W1964173823 cites W2027635015 @default.
- W1964173823 cites W2029542833 @default.
- W1964173823 cites W2031125523 @default.
- W1964173823 cites W2033291340 @default.
- W1964173823 cites W2035441514 @default.
- W1964173823 cites W2036478654 @default.
- W1964173823 cites W2036512797 @default.
- W1964173823 cites W2036790170 @default.
- W1964173823 cites W2042152382 @default.
- W1964173823 cites W2045185962 @default.
- W1964173823 cites W2045501862 @default.
- W1964173823 cites W2048144741 @default.
- W1964173823 cites W2050903686 @default.
- W1964173823 cites W2052617026 @default.
- W1964173823 cites W2053079851 @default.
- W1964173823 cites W2053651900 @default.
- W1964173823 cites W2058711118 @default.
- W1964173823 cites W2060974385 @default.
- W1964173823 cites W2061731402 @default.
- W1964173823 cites W2066439059 @default.
- W1964173823 cites W2066564897 @default.
- W1964173823 cites W2067795636 @default.
- W1964173823 cites W2068895093 @default.
- W1964173823 cites W2069102021 @default.
- W1964173823 cites W2069192879 @default.
- W1964173823 cites W2075069782 @default.
- W1964173823 cites W2078516661 @default.
- W1964173823 cites W2078612746 @default.
- W1964173823 cites W2081305223 @default.
- W1964173823 cites W2084253035 @default.
- W1964173823 cites W2087317982 @default.
- W1964173823 cites W2088274839 @default.
- W1964173823 cites W2090966488 @default.
- W1964173823 cites W2093639447 @default.
- W1964173823 cites W2100484879 @default.
- W1964173823 cites W2105916826 @default.
- W1964173823 cites W2106042714 @default.
- W1964173823 cites W2107985334 @default.
- W1964173823 cites W2116896173 @default.
- W1964173823 cites W2119979926 @default.
- W1964173823 cites W2120272723 @default.
- W1964173823 cites W2122532139 @default.
- W1964173823 cites W2131167630 @default.
- W1964173823 cites W2147197593 @default.
- W1964173823 cites W2148239264 @default.
- W1964173823 cites W2148479930 @default.
- W1964173823 cites W2151934215 @default.
- W1964173823 cites W2160194193 @default.
- W1964173823 cites W2161716973 @default.
- W1964173823 cites W2163898426 @default.
- W1964173823 cites W2318283658 @default.
- W1964173823 cites W2321928394 @default.
- W1964173823 cites W2329876251 @default.
- W1964173823 cites W4249505670 @default.
- W1964173823 doi "https://doi.org/10.1002/ddr.20144" @default.
- W1964173823 hasPublicationYear "2006" @default.
- W1964173823 type Work @default.
- W1964173823 sameAs 1964173823 @default.
- W1964173823 citedByCount "12" @default.
- W1964173823 countsByYear W19641738232013 @default.
- W1964173823 countsByYear W19641738232017 @default.